Details of the Drug Combination

General Information of Drug Combination (ID: DC1KIOO)

Drug Combination Name

MK-4815 Pyronaridine

Indication

Disease Entry	Status	REF
DD2	Investigative	[1]

Component Drugs

MK-4815 DMT9K74

Pyronaridine DMUWAM2

N.A.

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: DD2

Zero Interaction Potency (ZIP) Score: 24.427

Bliss Independence Score: 24.399

Loewe Additivity Score: 10.278

LHighest Single Agent (HSA) Score: 10.115

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of MK-4815

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Investigative	[2]

Indication(s) of Pyronaridine

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[3]

Pyronaridine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)	TTZVSJ2	NOUNIPROTAC	Inhibitor	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.